Covered recipient · General Payments record
YAN JI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$88,182.38
77 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $54,543.50 | 30 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,390.00 | 6 |
| Travel and Lodging | $5,832.76 | 28 |
| Honoraria | $1,650.00 | 1 |
| Food and Beverage | $758.11 | 11 |
| Education | $8.01 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $32,475.01 | 29 |
| AstraZeneca Pharmaceuticals LP | $21,088.20 | 11 |
| Merck Sharp & Dohme LLC | $9,463.36 | 9 |
| Janssen Biotech, Inc. | $7,853.85 | 10 |
| E.R. Squibb & Sons, L.L.C. | $4,404.07 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,323.01 | 3 |
| Amgen Inc. | $2,100.00 | 1 |
| BeOne Medicines USA, Inc. | $1,950.00 | 1 |
| Deciphera Pharmaceuticals Inc. | $1,840.98 | 5 |
| Novartis Pharmaceuticals Corporation | $1,655.53 | 2 |
| Genentech USA, Inc. | $997.50 | 1 |
| Janssen Scientific Affairs, LLC | $880.00 | 1 |
| Tempus AI, Inc | $150.87 | 1 |
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
YAN JI
NPI 1225355829 · CMS profile ID 1381109
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAINT PAUL, MN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- YAN JI, NPI 1225355829, CMS profile ID 1381109. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). YAN JI, NPI 1225355829, CMS profile ID 1381109. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- YAN JI, NPI 1225355829, CMS profile ID 1381109, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
77 matching records · $88,182.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–77 of 77.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $558.36 | 07/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238008504 | CMS |
| Merck Sharp & Dohme LLC | $70.28 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238029584 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,675.00 | 07/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206500234 | CMS |
| AstraZeneca Pharmaceuticals LP | $670.00 | 07/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206647989 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,015.00 | 07/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206382680 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,345.00 | 07/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207025374 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,010.00 | 06/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206495578 | CMS |
| Janssen Biotech, Inc. | $35.81 | 06/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915569 | CMS |
| Janssen Biotech, Inc. | $49.91 | 06/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915621 | CMS |
| Janssen Biotech, Inc. | $15.30 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915699 | CMS |
| Janssen Biotech, Inc. | $2,220.00 | 06/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915884 | CMS |
| Janssen Scientific Affairs, LLC | $880.00 | 05/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174174729 | CMS |
| Novartis Pharmaceuticals Corporation | $1,650.00 | 05/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200264650 | CMS |
| Janssen Biotech, Inc. | $142.50 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915718 | CMS |
| Janssen Biotech, Inc. | $283.86 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915830 | CMS |
| Janssen Biotech, Inc. | $446.97 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174915915 | CMS |
| Deciphera Pharmaceuticals Inc. | $1,650.00 | 05/01/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959666 | CMS |
| Deciphera Pharmaceuticals Inc. | $62.36 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959668 | CMS |
| Deciphera Pharmaceuticals Inc. | $64.92 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959670 | CMS |
| Deciphera Pharmaceuticals Inc. | $26.70 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959672 | CMS |
| Deciphera Pharmaceuticals Inc. | $37.00 | 05/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959674 | CMS |
| Tempus AI, Inc | $150.87 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250347285 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,040.00 | 03/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223786767 | CMS |
| Daiichi Sankyo Inc. | $1,387.50 | 02/19/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197037851 | CMS |
| Amgen Inc. | $2,100.00 | 01/23/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226908386 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,775.00 | 01/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184672769 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,010.00 | 01/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206249526 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,962,135.55 | 200 |
| PY2024 | Recipient | $4,470.00 | 3 |
| PY2024 | Principal investigator | $1,653,423.98 | 204 |
| PY2023 | Principal investigator | $717,665.96 | 73 |
| PY2022 | Principal investigator | $534,216.28 | 16 |
| PY2021 | Principal investigator | $311,490.01 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
200 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,923.52 | 12/31/2025 | Non-covered Recipient Entity Metro-Minnesota Community Clinical Oncology | MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With Next-generation Hormonal Agent NHA | No dispute reported | 06/30/2026 | 1232929167 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 12/22/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175365447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,300.00 | 12/22/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175365455 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,618.00 | 12/19/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183089 |
| Principal investigator 1 | Genentech, Inc. | $237.00 | 12/18/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625145 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625156 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,475.00 | 12/15/2025 | Non-covered Recipient Entity Healthpartners Institute For Education And Research | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1235996951 |
| Principal investigator 1 | Genentech, Inc. | $365.00 | 12/04/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625149 |
| Principal investigator 1 | Genentech, Inc. | $1,583.00 | 12/01/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625153 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 12/01/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718285 |
| Principal investigator 1 | Genentech, Inc. | $5,992.00 | 11/26/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612463 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 11/26/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716919 |
| Principal investigator 1 | PFIZER INC. | $945.00 | 11/26/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228807867 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 11/25/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739923 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807210 |
| Principal investigator 1 | PFIZER INC. | $37,632.15 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807216 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807223 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807320 |
| Principal investigator 1 | PFIZER INC. | $14,400.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807423 |
| Principal investigator 1 | PFIZER INC. | $4,800.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807430 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807504 |
| Principal investigator 1 | PFIZER INC. | $12,544.05 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807670 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228807764 |
| Principal investigator 1 | PFIZER INC. | $6,000.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807771 |
| Principal investigator 1 | PFIZER INC. | $4,800.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807776 |
| Principal investigator 1 | PFIZER INC. | $20,504.00 | 11/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807861 |
| Principal investigator 1 | BeOne Medicines Ltd. | $500.00 | 11/20/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334476 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,783.00 | 11/14/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183087 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 11/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716747 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 11/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717169 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 11/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718671 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 11/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718761 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $65,412.87 | 11/10/2025 | Covered Recipient Teaching Hospital Regions Hospital | A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190297873 |
| Principal investigator 1 | PFIZER INC. | $3,200.00 | 11/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228807315 |
| Principal investigator 1 | PFIZER INC. | $4,830.00 | 11/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228807326 |
| Principal investigator 1 | PFIZER INC. | $4,800.00 | 11/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228807852 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,618.00 | 11/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183085 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4,750.00 | 11/07/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739925 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $350.00 | 11/07/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739927 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,200.00 | 11/07/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739929 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 11/06/2025 | Non-covered Recipient Entity HEALTH PARTNERS INSTITUTE | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202523343 |
| Principal investigator 1 | BeOne Medicines Ltd. | $525.00 | 11/05/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329319 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 11/05/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334554 |
| Principal investigator 1 | BeOne Medicines Ltd. | $500.00 | 11/05/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334562 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,000.00 | 11/05/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334591 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,500.00 | 11/05/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334595 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,098.95 | 10/28/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235995759 |
| Principal investigator 1 | Astellas Pharma Global Development | $7,608.00 | 10/23/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183083 |
| Principal investigator 1 | PFIZER INC. | $32,820.00 | 10/15/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717005 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 10/15/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717007 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 10/15/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718427 |
| Principal investigator 1 | PFIZER INC. | $32,820.00 | 10/15/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718667 |
| Principal investigator 1 | Genentech, Inc. | $992.00 | 10/09/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612459 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,185.32 | 10/08/2025 | Non-covered Recipient Entity HEALTH PARTNERS MINNESOTA | ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy"; | No dispute reported | 06/30/2026 | 1185551553 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,220.00 | 10/08/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334497 |
| Principal investigator 1 | PFIZER INC. | $42,314.00 | 10/06/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228807664 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,250.00 | 10/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183075 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,400.00 | 10/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183077 |
| Principal investigator 1 | Astellas Pharma Global Development | $28,600.00 | 10/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183079 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,500.00 | 10/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE. | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) | No dispute reported | 06/30/2026 | 1234183081 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 10/02/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970214 |
| Principal investigator 1 | Genentech, Inc. | $992.00 | 10/01/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612455 |
| Principal investigator 1 | PFIZER INC. | $2,325.00 | 09/29/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228824375 |
| Principal investigator 1 | Genentech, Inc. | $5,192.00 | 09/25/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625142 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 09/22/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718423 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 09/22/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718759 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 09/19/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716921 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 09/19/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717103 |
| Principal investigator 1 | BeOne Medicines Ltd. | $495.00 | 09/17/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327367 |
| Principal investigator 1 | BeOne Medicines Ltd. | $236.00 | 09/12/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343258 |
| Principal investigator 1 | Genentech, Inc. | $1,984.00 | 09/04/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612448 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 09/03/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716745 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 09/03/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718495 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 09/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970199 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 09/02/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718499 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 09/02/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718502 |
| Principal investigator 1 | PFIZER INC. | $7,772.88 | 09/02/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228824370 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 08/30/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716923 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 08/30/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717105 |
| Principal investigator 1 | Genentech, Inc. | $26,575.00 | 08/26/2025 | Non-covered Recipient Entity HEALTH PARTNERS INSTITUTE EDUCATION + RESEARCH | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | No dispute reported | 06/30/2026 | 1211612359 |
| Principal investigator 1 | PFIZER INC. | $37,632.15 | 08/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228824416 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 08/25/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228824422 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,414.54 | 08/20/2025 | Non-covered Recipient Entity HEALTH PARTNERS MINNESOTA | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185551547 |
| Principal investigator 1 | PFIZER INC. | $35,922.00 | 08/18/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228826899 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228827627 |
| Principal investigator 1 | PFIZER INC. | $245.72 | 08/14/2025 | Non-covered Recipient Entity Metro MN Community Oncology | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228828936 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 08/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717003 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 08/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718757 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,089.08 | 08/07/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235995761 |
| Principal investigator 1 | Servier BioInnovation | $3,000.00 | 08/06/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970202 |
| Principal investigator 1 | Servier BioInnovation | $2,000.00 | 08/06/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970206 |
| Principal investigator 1 | Servier BioInnovation | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970210 |
| Principal investigator 1 | PFIZER INC. | $1,683.29 | 08/04/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228826617 |
| Principal investigator 1 | PFIZER INC. | $610.00 | 08/04/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228826623 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 08/04/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228826827 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 08/04/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228826894 |
| Principal investigator 1 | Genentech, Inc. | $992.00 | 07/31/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612451 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 07/28/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228807417 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 07/22/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739917 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $350.00 | 07/22/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739919 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $116.00 | 07/22/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739921 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 07/21/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718823 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 07/19/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717171 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,127.00 | 07/09/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327381 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,816.00 | 07/09/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331839 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,389.00 | 07/09/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343158 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 07/07/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718425 |
| Principal investigator 1 | PFIZER INC. | $8,227.41 | 07/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228830079 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 07/03/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717101 |
| Principal investigator 1 | Servier BioInnovation | $1,937.00 | 06/27/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970192 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 06/27/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970195 |
| Principal investigator 1 | PFIZER INC. | $32,820.00 | 06/23/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823161 |
| Principal investigator 1 | Genentech, Inc. | $5,530.17 | 06/09/2025 | Non-covered Recipient Entity MAYO CLINIC ROCHESTER REMIT PROCESSING | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211622940 |
| Principal investigator 1 | PFIZER INC. | $63,610.00 | 06/09/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228830054 |
| Principal investigator 1 | PFIZER INC. | $41,324.70 | 06/09/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228830061 |
| Principal investigator 1 | AstraZeneca UK Limited | $25,220.74 | 05/30/2025 | Non-covered Recipient Entity HEALTH PARTNERS MINNESOTA | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185551549 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 05/29/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228827008 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 05/28/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822488 |
| Principal investigator 1 | PFIZER INC. | $5,358.45 | 05/28/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228829481 |
| Principal investigator 1 | PFIZER INC. | $4,020.47 | 05/28/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228832759 |
| Principal investigator 1 | PFIZER INC. | $2,325.00 | 05/28/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228832778 |
| Principal investigator 1 | PFIZER INC. | $7,807.63 | 05/28/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228833316 |
| Principal investigator 1 | PFIZER INC. | $32,820.00 | 05/20/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228826587 |
| Principal investigator 1 | PFIZER INC. | $32,820.00 | 05/19/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822493 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 05/16/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320826 |
| Principal investigator 1 | BeiGene, Ltd. | $1,127.00 | 05/16/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325078 |
| Principal investigator 1 | PFIZER INC. | $87,993.36 | 05/12/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228827243 |
| Principal investigator 1 | AstraZeneca UK Limited | $9,200.00 | 05/07/2025 | Non-covered Recipient Entity HEALTH PARTNERS MINNESOTA | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185551551 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 05/06/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625134 |
| Principal investigator 1 | Genentech, Inc. | $4,288.00 | 05/06/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625139 |
| Principal investigator 1 | PFIZER INC. | $87,993.36 | 05/05/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823294 |
| Principal investigator 1 | PFIZER INC. | $3,100.00 | 05/05/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228832765 |
| Principal investigator 1 | BeiGene, Ltd. | $1,551.00 | 04/25/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320778 |
| Principal investigator 1 | BeiGene, Ltd. | $2,000.00 | 04/25/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320806 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 04/25/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322918 |
| Principal investigator 1 | BeiGene, Ltd. | $2,002.00 | 04/25/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322940 |
| Principal investigator 1 | BeiGene, Ltd. | $470.00 | 04/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320844 |
| Principal investigator 1 | PFIZER INC. | $30,092.25 | 04/21/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228832720 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/16/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228827693 |
| Principal investigator 1 | Genentech, Inc. | $1,984.00 | 04/15/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612440 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/15/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823253 |
| Principal investigator 1 | PFIZER INC. | $15,000.00 | 04/14/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1228833410 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 04/11/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228826581 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 04/10/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822429 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $931.50 | 04/08/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739915 |
| Principal investigator 1 | PFIZER INC. | $580.00 | 04/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228832744 |
| Principal investigator 1 | PFIZER INC. | $8,100.00 | 04/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228832868 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228832943 |
| Principal investigator 1 | PFIZER INC. | $37,282.00 | 04/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228833321 |
| Principal investigator 1 | PFIZER INC. | $2,532.58 | 04/07/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228833469 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $91,532.25 | 04/04/2025 | Non-covered Recipient Entity Healthpartners Institute | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | No dispute reported | 06/30/2026 | 1236531095 |
| Principal investigator 1 | PFIZER INC. | $65,995.02 | 04/01/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228826569 |
| Principal investigator 1 | PFIZER INC. | $128.00 | 03/31/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228833356 |
| Principal investigator 1 | Servier BioInnovation | $1,937.00 | 03/31/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970184 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 03/31/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970188 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $261,091.59 | 03/24/2025 | Covered Recipient Teaching Hospital Regions Hospital | A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190297083 |
| Principal investigator 1 | PFIZER INC. | $65,995.02 | 03/19/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823242 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 03/12/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320032 |
| Principal investigator 1 | BeiGene, Ltd. | $2,816.00 | 03/12/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320034 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 03/12/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324236 |
| Principal investigator 1 | PFIZER INC. | $36,800.00 | 03/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228832725 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 03/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228832845 |
| Principal investigator 1 | PFIZER INC. | $770.00 | 03/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228833423 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 02/28/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324218 |
| Principal investigator 1 | BeiGene, Ltd. | $1,380.00 | 02/28/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324272 |
| Principal investigator 1 | BeiGene, Ltd. | $257.00 | 02/28/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324612 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 02/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324222 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 02/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324336 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 02/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324354 |
| Principal investigator 1 | BeiGene, Ltd. | $1,127.00 | 02/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324380 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 02/21/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324616 |
| Principal investigator 1 | Celgene Corporation | $5,847.55 | 02/21/2025 | Non-covered Recipient Entity Healthpartners Institute For Education And Research | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305614 |
| Principal investigator 1 | ABBVIE INC. | $8,000.00 | 02/20/2025 | Non-covered Recipient Entity HEALTH PARTNERS INSTITUTE | M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202453217 |
| Principal investigator 1 | PFIZER INC. | $1,246.00 | 02/18/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228832755 |
| Principal investigator 1 | PFIZER INC. | $1,507.00 | 02/18/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228833403 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 02/18/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228833434 |
| Principal investigator 1 | Genentech, Inc. | $12,000.00 | 02/17/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625121 |
| Principal investigator 1 | Genentech, Inc. | $1,984.00 | 02/11/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211612444 |
| Principal investigator 1 | PFIZER INC. | $14,138.55 | 02/10/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228833452 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 02/06/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228827122 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,903.76 | 02/04/2025 | Non-covered Recipient Entity INTERIM HEALTH CARE | A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190309750 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 02/03/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320116 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 02/03/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320122 |
| Principal investigator 1 | PFIZER INC. | $54,995.85 | 02/03/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823155 |
| Principal investigator 1 | PFIZER INC. | $5,658.00 | 02/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228832802 |
| Principal investigator 1 | PFIZER INC. | $820.00 | 02/03/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228833327 |
| Principal investigator 1 | Genentech, Inc. | $3,601.00 | 01/30/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625124 |
| Principal investigator 1 | Genentech, Inc. | $237.00 | 01/30/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625127 |
| Principal investigator 1 | BeiGene, Ltd. | $2,389.00 | 01/29/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324260 |
| Principal investigator 1 | Celgene Corporation | $24,842.15 | 01/29/2025 | Non-covered Recipient Entity Healthpartners Institute For Education And Research | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305564 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $621.00 | 01/29/2025 | Non-covered Recipient Entity HEATLHPARTNERS INSTITUTE | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233739913 |
| Principal investigator 1 | BeiGene, Ltd. | $695.00 | 01/27/2025 | Non-covered Recipient Entity HealthPartners Institute | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324372 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 01/17/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970178 |
| Principal investigator 1 | Servier BioInnovation | $1,532.00 | 01/17/2025 | Non-covered Recipient Entity HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235970181 |
| Principal investigator 1 | Genentech, Inc. | $128.00 | 01/09/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium-MMCOrc | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211625130 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,297.50 | 01/09/2025 | Non-covered Recipient Entity METROPOLITAN MINNESOTA CCOP | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190306477 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,768.08 | 01/09/2025 | Non-covered Recipient Entity METROPOLITAN MINNESOTA CCOP | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) | No dispute reported | 06/30/2026 | 1190306479 |
| Principal investigator 1 | PFIZER INC. | $65,995.02 | 01/09/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228827118 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 01/06/2025 | Non-covered Recipient Entity Regions Hospital | A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent,metastatic head and neck squamous cell carcinoma KEYNOTE-B10 | No dispute reported | 06/30/2026 | 1232927957 |
| Principal investigator 1 | PFIZER INC. | $65,995.02 | 01/02/2025 | Non-covered Recipient Entity Metro Minnesota Community Oncology Research Consortium | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228823247 |